133 related articles for article (PubMed ID: 35166091)
1. Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation.
D'Amario D; Galli M; Cappannoli L; Canonico F; Restivo A; Arcudi A; Scacciavillani R; Riccioni ME; Vergallo R; Montone RA; Conte A; Meleo E; Lancellotti S; Sacco M; Antonelli M; Andreotti F; DE Cristofaro R; Crea F
Minerva Cardiol Angiol; 2023 Feb; 71(1):109-116. PubMed ID: 35166091
[TBL] [Abstract][Full Text] [Related]
2. ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study.
D'Amario D; Galli M; Canonico F; Restivo A; Arcudi A; Scacciavillani R; Cappannoli L; Riccioni ME; Annetta MG; Di Stefano G; Piccinni C; Vergallo R; Montone RA; Leone AM; Niccoli G; Sabatelli M; Antonelli M; Andreotti F; De Cristofaro R; Crea F
J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):175-179. PubMed ID: 33186237
[TBL] [Abstract][Full Text] [Related]
3. Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study.
Cappannoli L; Laborante R; Galli M; Canonico F; Ciliberti G; Restivo A; Princi G; Arcudi A; Sabatelli M; De Cristofaro R; Crea F; D'Amario D
Front Cardiovasc Med; 2022; 9():1052053. PubMed ID: 36620634
[TBL] [Abstract][Full Text] [Related]
4. Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy.
Galli M; D'Amario D; Andreotti F; Porto I; Vergallo R; Sabatelli M; Lancellotti S; Meleo E; De Cristofaro R; Crea F
ESC Heart Fail; 2019 Aug; 6(4):884-888. PubMed ID: 31184800
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
[TBL] [Abstract][Full Text] [Related]
7. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
[TBL] [Abstract][Full Text] [Related]
9. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban: A direct oral anticoagulant.
Poulakos M; Walker JN; Baig U; David T
Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Chen J; Zhuang X; Long M; Su C; Wang L
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
[TBL] [Abstract][Full Text] [Related]
12. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Dzeshka MS; Lip GY
Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069
[TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
15. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
16. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban, a Novel Oral Factor Xa Inhibitor.
Minor C; Tellor KB; Armbruster AL
Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
[TBL] [Abstract][Full Text] [Related]
18. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review.
Lowenstern A; Al-Khatib SM; Sharan L; Chatterjee R; Allen LaPointe NM; Shah B; Borre ED; Raitz G; Goode A; Yapa R; Davis JK; Lallinger K; Schmidt R; Kosinski AS; Sanders GD
Ann Intern Med; 2018 Dec; 169(11):774-787. PubMed ID: 30383133
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
20. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]